ArriVent BioPharma, Inc. AVBP Other comprehensive income (loss)
Other comprehensive income (loss) at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossNetOfTax.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s other comprehensive income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s other comprehensive income (loss)?
- ArriVent BioPharma, Inc. (AVBP) reported other comprehensive income (loss) of -$284K in Q1 2026.
- How has ArriVent BioPharma, Inc.'s other comprehensive income (loss) changed year-over-year?
- ArriVent BioPharma, Inc.'s other comprehensive income (loss) decreased by 246.4% year-over-year, from $194K to -$284K.
- What does other comprehensive income (loss) mean?
- This metric captures all revenues, expenses, gains, and losses that are excluded from net income under accounting standards but are recognized directly in equity. It typically includes items such as foreign currency translation adjustments and unrealized gains or losses on specific financial instruments. It provides a more comprehensive view of changes in shareholder equity beyond the traditional net income figure.